{
    "organizations": [],
    "uuid": "8c7d9f9bccd265f15da49410ea5d65e2ab1e557b",
    "author": "",
    "url": "https://www.reuters.com/article/brief-psivida-says-fda-accepts-nda-for-p/brief-psivida-says-fda-accepts-nda-for-posterior-segment-uveitis-treatment-idUSASC09SUF",
    "ord_in_thread": 0,
    "title": "BRIEF-pSivida Says FDA Accepts NDA For Posterior Segment Uveitis Treatment",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 19, 2018 / 6:28 PM / Updated 12 minutes ago BRIEF-pSivida Says FDA Accepts NDA For Posterior Segment Uveitis Treatment Reuters Staff 1 Min Read March 19 (Reuters) - pSivida Corp: * PSIVIDA ANNOUNCES FDA ACCEPTANCE FOR FILING OF NEW DRUG APPLICATION (NDA) FOR DURASERT THREE-YEAR TREATMENT FOR POSTERIOR SEGMENT UVEITIS * APPLICATION WILL HAVE PDUFA DATE OF NOVEMBER 5 Source text for Eikon: Further company coverage:",
    "published": "2018-03-19T20:25:00.000+02:00",
    "crawled": "2018-03-19T20:43:26.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "pm",
        "updated",
        "minute",
        "ago",
        "say",
        "fda",
        "accepts",
        "nda",
        "posterior",
        "segment",
        "uveitis",
        "treatment",
        "reuters",
        "staff",
        "min",
        "read",
        "march",
        "reuters",
        "psivida",
        "corp",
        "psivida",
        "announces",
        "fda",
        "acceptance",
        "filing",
        "new",
        "drug",
        "application",
        "nda",
        "durasert",
        "treatment",
        "posterior",
        "segment",
        "uveitis",
        "application",
        "pdufa",
        "date",
        "november",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}